Wounds and the Microbiome

Wounds are the most common and most costly skin disease. Immediately upon injury to the skin, the wound becomes colonized by bacteria and a biofilm quickly emerges thereafter. Research data has now accumulated on biofilms in wounds and interventions are available on the market.

The Decision to Go Systemic

Treating AD with systemic medications is reserved for difficult patients. When should the treating clinician make the call to initiate systemic therapy?

The Big Meds

Systemic agents can change the life of people with AD. In this module, systemic therapies are reviewed through illustrative cases. The best agent is chosen based on disease severity, patient choices, side effects profile, and other considerations.

Big Meds, Little Patients

Initiating systemic therapy for kids with AD is a difficult decision. Through case-based examples, a step-by-step approach is presented to safely navigate this difficult problem.

The Follow-Up Visit

Once systemic therapy is initiated the journey only begins. Through case-based learning, questions pertaining to dosing, adverse effects, monitoring and treatment cessation are explored.

The Future Is Here

New systemic therapies for moderate to severe AD are arriving in the market. How do these molecules work in AD? How are they best utilized? Illustrative cases demonstrate the role for these life-changing therapies in AD management.

The Itch Synergy

Itch is the quintessential symptom of AD. Choosing the best systemic therapy for AD that will also synergize with the patient’s itch is an opportunity often missed. Through case-based learning, the pathways of itch in AD are reviewed and potential therapies are offered.

Strategies for Spironolactone and Isotretinoin Use in Acne and HS

In this webinar, we review the basic virology of COVID-19 (SARS-CoV-2), including the cellular entry pathways through the ACE2 receptor. We then discuss the use of spironolactone and its possible association to ACE2 expression. We conclude with case studies and explore the use of isotretinoin from a practical perspective in the setting of physically distant management and COVID-19 infection.

Managing Use of Systemic Immunosuppressive Medications: HS, Psoriasis, Atopic Dermatitis, Bullous Diseases, and Beyond

General immunosuppression can heighten the risk for infections, and this webinar will detail the risk for viral infections with immunosuppression and discuss strategies for immunosuppressive and immunomodulatory medication management during the COVID-19 pandemic.

Practical Approaches to Teledermatology: Billing, Coding, and More

Are you new to teledermatology or want to optimize your telederm visits? In this webinar, we share secrets to success when implementing new teledermatology approaches to patient care, including time-based billing and which rules to use, coding, documentation, precautions when seeing pediatric patients, and features to look for in a platform!

Recent Advances in Moderate to Severe Atopic Dermatitis Etiology and Management

This session will explore novel therapeutic targets that are emerging with greater understanding of the pathophysiology of Atopic Dermatitis.

2020 Integrative Dermatology Symposium Lectures

Recordings and handouts from 2020 integrative dermatology symposium 

The Approach to Hidradenitis Suppurativa in Those with Skin of Color

This session will review how the prevalence and clinical presentation of HS may be altered in those with skin of color. The unique sequelae on the skin will be discussed along with the need to alter the therapeutic approach.

Shared Decision Making in Hidradenitis Suppurativa: An Integrative Approach

This session will review the importance of shared decision making and how to most effectively involve the patient in diagnosis and treatment related discussions. The role of understanding the patient’s treatment and cultural perspectives will be explored along with how to incorporate discussions around pharmaceutical and nutrition based approaches. 

Expert Panel on Hidradenitis Suppurativa

This live course panel of expert dermatologists will discuss multiple cases of HS focused on diagnosis and management.

The Emergence of JAK/TEC Inhibitors and IL-17/23 Biologics

Join a global discussion on the emerging use of IL-17/23 inhibiting biologics, JAK inhibitors, and TEC inhibitors in clinical practice. Explore the evidence surrounding their safety and efficacy, referencing existing literature and expert insights. Stay informed about the latest advancements in these therapeutic approaches.

Microbiome and the Universe Within Us

COVID-19

Hidradenitis Suppurativa: Examining the Role of Immunology and Inflammation with Biologics and JAK Inhibition

2025 Integrative Dermatology Symposium Lectures

Hidradenitis Suppurativa Series